METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF Russian patent published in 2019 - IPC A61K38/36 C07K16/36 

FIELD: biotechnologies.

SUBSTANCE: invention relates to the biotechnology. Described is a method for reducing the risk and/or prevention of an acute episode of vWF-dependent disease in a human in need thereof, involving the steps of: (i) measuring ADAMTS13 activity in said individual; (ii) comparing said ADAMTS13 activity with standard ADAMTS13 activity; and (iii) if said ADAMTS13 activity is less than 30 %, having such value as 20 %, 15 %, 10 % or 5 % of said standard activity of ADAMTS13, administering to said human dose of 5–40 mg, preferably 10 mg, a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) for von Willebrand factor (vWF), wherein said polypeptide contains or consists of SEQ ID NO: 1–19. Also described is a method of treating a vWF-dependent disease in a human in need thereof, comprising administering a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) von Willebrand factor (vWF) unless ADAMTS13 activity reaches at least 10 %, such as at least 15 %, 20 %, 25 %, 30 %, 35 %, 45 % or even 50 % from standard ADAMTS13 activity, wherein said polypeptide contains or consists of SEQ ID NO: 1–19. Also described is a method of treating vWF-dependent disease in a human in need thereof, involving at least the following stages: (i) performing plasma exchange (SW); (ii) administering to a human subject dose of 5–40 mg, preferably 10 mg of a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand factor (vWF); (iii) determining ADAMTS13 activity in said patient; (iv) comparing said ADAMTS13 activity with standard ADAMTS13 activity; and (v) if said ADAMTS13 activity is below 30 %, as 20 %, 15 %, 10 % or 5 % of said standard activity of ADAMTS13, repeating said step (ii) and optionally step (i), where said steps (i) and step (ii) are repeated once a day or twice a day, wherein said polypeptide contains or consists of SEQ ID NO: 1–19.

EFFECT: invention provides considerable reduction of time to response in people suffering from TTP.

19 cl, 6 dwg, 12 tbl